EP1119353A4 - Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine - Google Patents

Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine

Info

Publication number
EP1119353A4
EP1119353A4 EP99950209A EP99950209A EP1119353A4 EP 1119353 A4 EP1119353 A4 EP 1119353A4 EP 99950209 A EP99950209 A EP 99950209A EP 99950209 A EP99950209 A EP 99950209A EP 1119353 A4 EP1119353 A4 EP 1119353A4
Authority
EP
European Patent Office
Prior art keywords
limocitrin
sinensetin
desmethyl
compositions
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99950209A
Other languages
German (de)
English (en)
Other versions
EP1119353A1 (fr
Inventor
Najla Guthrie
John A Manthey
Robert M Horowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KGK Synergize Inc
US Department of Agriculture USDA
Original Assignee
KGK Synergize Inc
US Department of Agriculture USDA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KGK Synergize Inc, US Department of Agriculture USDA filed Critical KGK Synergize Inc
Publication of EP1119353A1 publication Critical patent/EP1119353A1/fr
Publication of EP1119353A4 publication Critical patent/EP1119353A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP99950209A 1998-10-06 1999-10-05 Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine Withdrawn EP1119353A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16763498A 1998-10-06 1998-10-06
US167634 1998-10-06
PCT/US1999/023238 WO2000019998A1 (fr) 1998-10-06 1999-10-05 Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine

Publications (2)

Publication Number Publication Date
EP1119353A1 EP1119353A1 (fr) 2001-08-01
EP1119353A4 true EP1119353A4 (fr) 2002-08-28

Family

ID=22608155

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99950209A Withdrawn EP1119353A4 (fr) 1998-10-06 1999-10-05 Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine

Country Status (5)

Country Link
EP (1) EP1119353A4 (fr)
JP (2) JP2003509334A (fr)
AU (1) AU6291699A (fr)
CA (1) CA2346333A1 (fr)
WO (1) WO2000019998A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6987125B1 (en) 1998-10-06 2006-01-17 The United States Of America As Represented By The Secretary Of Agriculture Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
US20060135445A1 (en) * 2003-02-04 2006-06-22 Kabushiki Kaisha Yakult Honsha Breast cancer-resistant protein inhibitor
JP2008513350A (ja) * 2005-05-24 2008-05-01 ケージーケー シナジャイズ インコーポレイテッド フラボノイドとトコトリエノールを含む組成物及びその方法
WO2008035208A2 (fr) * 2006-05-19 2008-03-27 Kgk Synergize Inc Utilisation de flavonoïdes pour inhiber la croissance cellulaire
CN102731459B (zh) * 2012-06-15 2014-05-28 南京中医药大学 灯盏乙素苷元Mannich衍生物及其制备方法和应用
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
KR20230161639A (ko) * 2022-05-19 2023-11-28 제주대학교 산학협력단 제주쑥 추출물을 함유하는 항암용 조성물
CN115813991A (zh) * 2022-11-29 2023-03-21 三峡大学 一种柑橘属果实提取物在制备治疗乳腺癌内分泌药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867541A (en) * 1972-05-03 1975-02-18 Ralph C Robbins Compositions and methods for disaggregating blood cells
US3903266A (en) * 1972-05-03 1975-09-02 Ralph C Robbins Compositions and methods for disaggregating blood cells
JPH0617304B2 (ja) * 1982-09-09 1994-03-09 理化学研究所 制癌剤
JPH06116164A (ja) * 1992-10-07 1994-04-26 Otsuka Pharmaceut Co Ltd 癌の併用化学療法剤
ZA941290B (en) * 1993-02-26 1995-08-25 Res Dev Foundation Combination cisplatin/tamoxifen therapy for human cancers
US5336685A (en) * 1993-04-12 1994-08-09 Sloan-Kettering Institute For Cancer Research Use of flavonoids to treat multidrug resistant cancer cells
JPH08310952A (ja) * 1995-03-16 1996-11-26 Takeda Chem Ind Ltd 医薬組成物
JP2000500138A (ja) * 1995-11-07 2000-01-11 イーライ・リリー・アンド・カンパニー 耐性腫瘍の治療方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUTHRIE N ET AL: "INHIBITION OF MAMMARY CANCER BY CITRUS FLAVONOIDS", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 439, 1998, pages 227 - 236, XP000995351, ISSN: 0065-2598 *
See also references of WO0019998A1 *

Also Published As

Publication number Publication date
WO2000019998A1 (fr) 2000-04-13
CA2346333A1 (fr) 2000-04-13
EP1119353A1 (fr) 2001-08-01
JP2005015469A (ja) 2005-01-20
JP2003509334A (ja) 2003-03-11
AU6291699A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
PL335421A1 (en) Method of preventing and retarding occurence of alzheimer diseases as well as preparation therefor
IL142865A0 (en) Methods and compositions for the prevention of tolerance to medications
HK1037303A1 (en) Compositions and methods for treatment of mitochondrial diseases
IL140214A0 (en) Butterlike compositions and methods of manufacturing same
EP1005330A4 (fr) Procedes et compositions permettant de cibler des composes vers des muscles
ZA959438B (en) Hemorrhoidal compositions and method of use
HK1038744A1 (zh) 用於治療炎性疾病的化合物
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
EP1119255A4 (fr) Nouvelles compositions et nouveaux procedes destines a la prevention et au traitement de maladies provoquees par des protozoaires
PL329308A1 (en) Derivatives of aminoisoquinoline and aminothienepyridine as well as their application as antinflammatory agents
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
EP1045689A4 (fr) Synthese de phenstatine et promedicaments de celle-ci
PL330981A1 (en) Compositions of throwafloxacin mesilate
GB2348199B (en) Corrosion inhibitor compositions and methods of making them
EP1119353A4 (fr) Compositions et procedes pouvant inhiber des maladies neoplastiques au moyen de composes apparentes a limocitrine et 5-desmethyl-sinensetine
HUP0003679A3 (en) Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases
GB9405229D0 (en) Compositions of matter
IL141426A0 (en) Compositions and methods for the treatment of tumor
HUP9904332A3 (en) Compositions and articles of manufacture
GB9409944D0 (en) New compositions of matter
AU2003236439A1 (en) Compositions and Methods of Inhibiting Neoplastic Diseases With Compounds Related to Limocitrin and 5-Desmethyl Sinensetin
GB9405234D0 (en) New compositions of matter
GB9613410D0 (en) Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
HK1037139A1 (en) Novel uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same
SI1124563T1 (en) Methods and compositions for the prevention of tolerance to bronchodilators

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010419

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020711

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030718